Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost RDR versus Xalatan for ocular hypertension and primary open-angle glaucoma
ISRCTN80385690Phase 3Completed
- Sponsor
- RDR Pharma
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by RDR Pharma. Primary endpoint: Mean change in 8 AM intraocular pressure from baseline to end of study in the study eye. Started May 2009; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on ISRCTN80385690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80385690.